Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
NCT00895245
Terminated
RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoi... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/13/2017
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Register for Updates
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
NCT01355302
Terminated
The purpose of this study is to determine the following: 1. Find the maximum tolerated dose of E7050 when given in combination with cisplatin and capecitabine in patients with advance or metastatic solid tumors, and 2) Whether E7050 in combination with cisplatin and capecitabine is more effective in patients with previously untreated gastric cancer versus cisplatin and capecitabine alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/07/2017
Locations: Arizona Oncology Associates, PC - CASA, Tucson, Arizona +18 locations
Conditions: Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer
Register for Updates
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
NCT00227539
Completed
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET), (done before, during, and after chemotherapy) may help doctors predict a patient's response to treatment and help plan the best treatment. Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy after surgery may kill any tumor cells that remain after su... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/31/2017
Locations: Seattle Cancer Care Alliance, Seattle, Washington +1 locations
Conditions: Lung Cancer
Register for Updates
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC
NCT02276560
Terminated
The purpose of this research study is to determine whether giving cisplatin and nab-paclitaxel before surgery will reduce the presence of disease in certain areas of the lung at the time of surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2017
Locations: Moffitt Cancer Center, Tampa, Florida +8 locations
Conditions: Stage IIIA Non-Small Cell Lung Cancer
Register for Updates
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
NCT00025259
Completed
This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more ef... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/15/2017
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +174 locations
Conditions: Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Register for Updates
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
NCT00551512
Completed
The purpose of this research study is to find the answers to the following questions: 1. What are the highest doses of CBP501 and cisplatin that can be safely administered as consecutive 2-hours and 1-hour infusions every 21 days? 2. What are the side effects of the combination of CBP501 and cisplatin when given as an infusion every 21 days? 3. What amount of CBP501 and cisplatin are found in the blood at certain times after it is given? 4. Are there any substances in your blood or tumor that c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2017
Locations: Scottsdale Clinical Research Institute, Scottsdale, Arizona +2 locations
Conditions: Cancer, Solid Tumors
Register for Updates
Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma
NCT00707161
Terminated
The study is a prospective phase II trial of radiation therapy concurrent with cisplatin chemotherapy in the treatment of locally advanced or metastatic melanoma in patients who are deemed to require radiation therapy by treating physicians for purposes of local control or palliation. Eligibility criteria include pathologically confirmed melanoma. Patients will undergo radiation therapy (20 treatments of 2.5 Gy for a total of 50 Gy) concurrent with cisplatin chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/01/2017
Locations: Huntsman Cancer Institute, Salt Lake City, Utah +1 locations
Conditions: Cancer, Melanoma
Register for Updates
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
NCT01240590
Completed
Background: Anaplastic thyroid cancer (ATC) is one of the most aggressive of all solid tumors; chemotherapy and surgery have had no impact on local control or survival of patients, with a median survival of 3-7 months. Crolibulin (EPC2407) is a microtubulin inhibitor that has been shown to have direct antitumor effects in vivo and in vitro, destabilizing spindles and inducing apoptosis, resulting in the disruption of neovascular endothelial cells with disruption of blood flow to the tumor. Ear... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/27/2017
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Solid Tumor, Anaplastic Thyroid Cancer
Register for Updates
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
NCT00513383
Completed
This study is being done to test whether panitumumab, in combination with chemotherapy and radiation is safe in people with head and neck cancer. Another goal of this study is to find the highest dose of the study drugs that can be given safely without causing serious sife effects. Panitumumab is a type of drug called a monoclonal antibody that has been studied in other types of cancers, such as kidney and colon. This monoclonal antibody is directed against the epidermal growth factor receptor (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2017
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
NCT00504751
Completed
Objectives The primary objective of this study is to: • determine the complete and partial response rates and the toxicity profile of bortezomib (VELCADE, formerly PS-341) when administered in combination with DICE chemotherapy plus rituximab (i.e. VIPER) to patients with relapsed or refractory diffuse large B-cell non-Hodgkin's lymphoma The secondary objectives of this study are to: * assess event free survival and overall survival * assess conversion of chemo-resistant to chemo-sensitive d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2017
Locations: Weill Cornell Medical College, New York, New York
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
NCT00863512
Terminated
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, cisplatin, docetaxel, gemcitabine, and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sometimes after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether chemotherapy is more effective than observation in treating patients who have undergone surgery for st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2017
Locations: Regional Medical Center, Anniston, Alabama +93 locations
Conditions: Lung Cancer
Register for Updates
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
NCT01659554
Terminated
The primary objective of this study is to investigate the feasibility, tolerability and safety of surgical debulking and resection with heated intraoperative chemotherapy (HIPEC) followed by repeated intraperitoneal chemotherapy for treatment of recurrent ovarian, primary peritoneal, and fallopian tube carcinomas.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/30/2017
Locations: Columbia University Medical Center, New York, New York
Conditions: Recurrent Ovarian Cancer, Fallopian Tube Cancer
Register for Updates